arrow_back Back to App

Drug Price Negotiation: Extended Period for Small-Molecule Drugs.

This bill aims to extend the drug price negotiation period for small-molecule drugs under the Drug Price Negotiation Program. This means drug manufacturers will have more time to negotiate prices with the government, potentially impacting the availability and cost of certain medications for citizens.
Key points
Extends the negotiation period for small-molecule drugs from 7 to 11 years.
Aims to equalize negotiation periods between small-molecule and biologic drugs.
May influence drug pricing and accessibility in the market.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1492
Sponsor: Rep. Murphy, Gregory F. [R-NC-3]
Process start date: 2025-02-21
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1492.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-21.

What are the main provisions?

Key points include:

  • Extends the negotiation period for small-molecule drugs from 7 to 11 years.
  • Aims to equalize negotiation periods between small-molecule and biologic drugs.
  • May influence drug pricing and accessibility in the market.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Murphy, Gregory F. [R-NC-3].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health